Sunflower Pharmaceutical Group Co.,Ltd

Equities

002737

CNE100001WT7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 06/06/2024 BST 5-day change 1st Jan Change
29.89 CNY -0.70% Intraday chart for Sunflower Pharmaceutical Group Co.,Ltd +3.97% +15.05%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation MT
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chinese Drug Regulator Accepts Application of Sunflower Pharma's Unit for Fexofenadine Hydrochloride Oral Suspension MT
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sunflower Pharma Buys Local Drug Distributor for 2.3 Million Yuan MT
Sunflower Pharmaceutical Group Co.,Ltd agreed to acquire Hainan Huihai Pharmaceutical Co., Ltd. from Tonghua Huikang Biopharmaceutical Co., Ltd. and Kang Jia for CNY 2.3 million CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020. CI
Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback announced on December 24, 2020, has expired with 3,838,503 shares, representing 0.66% for CNY 56.33 million. CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020. CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020. CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020. CI
Sunflower Pharmaceutical : Pharma Buys Back More Shares in Two Months MT
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020. CI
Sunflower Pharmaceutical Group Co.,Ltd announces an Equity Buyback for CNY 100 million worth of its shares. CI
Chart Sunflower Pharmaceutical Group Co.,Ltd
More charts
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Company’s main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002737 Stock
  4. News Sunflower Pharmaceutical Group Co.,Ltd
  5. China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW